2024-10-10T17:24:52+08:002023-03-30|
Contact Information
Title
Research Assistant Professor
Office
(Office) N22-3003
Phone
(Office) +853 8822 2964
Email
juminhuang@um.edu.mo
Teaching

GEST1002 Quantitative Reasoning for Social Science

Research Team
Name Position Office Phone Email
Dr Jumin HUANGResearch Assistant ProfessorN22-3003+853 8822 2964juminhuang@um.edu.mo
Tingting ZHAOPost-doctoral FellowN22-3004+853 8822 2964tingtingzhao@um.edu.mo
Yinrui GUOPost-doctoral Fellow (Macau Young Scholar Program)N22-3004+853 8822 2964yinruiguo@um.edu.mo
Jin LIAOResearch AssistantN22-3003+853 8822 2964jinliao@um.edu.mo
Rongsheng SHENResearch AssistantN22-3004+853 8822 2964rongshengshen@um.edu.mo
Yongkai LiangResearch AssistantN22-3003+853 8822 2964yongkailiang@um.edu.mo
Jiahui XUPhD StudentN22-3003+853 8822 2964yc27654@um.edu.mo
Ziming WANGPhD StudentN22-3003+853 8822 2964yc27657@um.edu.mo
Ziwen YUPhD StudentN22-3003+853 8822 2964yc37632@um.edu.mo
Xiaoxian KUANGPhD StudentN22-3003+853 8822 2964yc37189@um.edu.mo
Shuyun JIANGPhD StudentN22-3003+853 8822 2964yc37643@um.edu.mo
Chun XIEPhD StudentN22-3003+853 8822 2964yc47691@um.edu.mo
Shujie SONGPhD StudentN22-3003+853 8822 2964yc47620@um.edu.mo
Yuqing NUPhD StudentN22-3003+853 8822 2964yc47602@um.edu.mo
Education
PhD Macau University of Science and Technology (2021)
MSc Jiangxi University of TCM (2016)
BSc Chengdu University of TCM (2013)
Position
02/2024 – Present Research Assistant Professor, Faculty of Health Sciences, University of Macau
11/2022 – 01/2024 Postdoctoral fellow, Faculty of Health Sciences, University of Macau (FDCT Funding Scheme)
01/2022 – 09/2022 Postdoctoral fellow, Macau University of Science and Technology (FDCT Funding Scheme)
10/2016 – 07/2018 Research Assistant, Macau University of Science and Technology
Research Interests
  1. Interactions among TCM-Neuroendocrine-Tumor Immunology-Gut Microbiota
  2. Research and development of TCM aromatherapy healthy products
Representative Publications
  1. Zhang, Y.Z., Lai, H.L., Huang, C., Jiang, Z.B., Yan, H.X., Wang, X.R., Xie, C., Huang, J.M., Ren, W.K., Li, J.X., et al. (2024). Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer. Phytomedicine 128, 155431. 10.1016/j.phymed.2024.155431. (IF: 6.7)
  2. Xu J-H, Wang S-J, Wang Z, Huang J, Xie C, Cao Y, Chen M, Leung EL-H. Evolution of resistance to KRASG12C inhibitor in a non-small cell lung cancer responder. bioRxiv: 2023.12.18.572090, 2023.
  3. Huang J*, Wang X, Wang Z, Deng L, Wang Y, Tang Y, Luo L, Leung EL. Extracellular vesicles as a novel mediator of interkingdom communication. Cytokine Growth Factor Rev, 2023. (IF: 13.0)
  4. Huang J*, Duan F, Xie C, Xu J, Zhang Y, Wang Y, Tang YP, Leung EL. Microbes mediated immunogenic cell death in cancer immunotherapy. Immunol Rev, 2023. (IF: 8.7)
  5. Tian W*, Huang J*, Zhang W, Wang Y, Jin R, Guo H, Tang Y, Wang Y, Lai H, Leung EL. Harnessing natural product polysaccharides against lung cancer and revisit its novel mechanism. Pharmacol Res 199: 107034, 2023. (IF: 9.3；Co-first author)
  6. Huang J*, Liu D*, Wang Y*, Liu L, Li J, Yuan J, Jiang Z, Jiang Z, Hsiao WW, Liu H, Khan I, Xie Y, Wu J, Xie Y, Zhang Y, Fu Y, Liao J, Wang W, Lai H, Shi A, Cai J, Luo L, Li R, Yao X, Fan X, Wu Q, Liu Z, Yan P, Lu J, Yang M, Wang L, Cao Y, Wei H, Leung EL-H. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the anti-tumour effect of anti-programmed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy. Gut 2022; 71: 734-745. (IF: 31.795, ESI Highly Cited Paper)
  7. Leung EL-H*, Fan X-X*, Huang J-M*, Huang C, Lin H, Cao Y-B. Holistic immunomodulation for small cell lung cancer. Seminars in Cancer Biology (IF: 17.012；Co-first author)
  8. Zhang J*, He J*, Huang J*, Li X, Fan X, Li W, Wu G, Xie C, Fan X X, Zhang J, Yao X, Wang R, and Leung E L, Pharmacokinetics, absorption and transport mechanism for ginseng polysaccharides. Biomed Pharmacother, 2023. 162: p. 114610. (IF: 7.419；Co-first author)
  9. Leung EL*, Huang J*, Zhang J*, Zhang J, Wang M, Zhu Y, Meng Z, Yu H, Neher E, Ma L, Yao XJ. Novel anticancer strategy by targeting the gut microbial neurotransmitter signaling to overcome immunotherapy resistance. Antioxid Redox Signal (IF: 7.468；Co-first author)
  10. Huang J*, Jiang Z*, Wang Y*, Fan X, Cai J, Yao X, Liu L, Huang J, He J, Xie C, Wu Q, Cao Y, Leung EL. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy. Curr Opin Pharmacol 2020; 54: 1-10. (IF: 5.547)
  11. Leung EL*, Li RZ*, Fan XX*, Wang LY, Wang Y, Jiang Z, Huang J, Pan HD, Fan Y, Xu H, Wang F, Rui H, Wong P, Sumatoh H, Fehlings M, Nardin A, Gavine P, Zhou L, Cao Y, Liu L. Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy. Nat Commun 14: 5115, 2023. (IF: 17.694)
  12. Wang J, Li RZ, Wang WJ, Pan HD, Xie C, Yau LF, Wang XX, Long WL, Chen RH, Liang TL, Ma LR, Li JX, Huang JM, Wu QB, Liu L, He JX, Leung EL. CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8(+)Tim3(+) exhausted T cells in non-small cell lung cancer. Pharmacol Res: 106850, 2023. (IF: 9.3)
  13. Xu C, Jiang Z B, Shao L, Zhao Z M, Fan X X, Sui X, Yu L L, Wang X R, Zhang R N, Wang W J, Xie Y J, Zhang Y Z, Nie X W, Xie C, Huang J M, Wang J, Wang J, Leung E L, and Wu Q B, beta-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer. Pharmacol Res, 2023. 191: p. 106739. (IF: 10.334)
  14. Fan X*, Mai C*, Zuo L*, Huang J, Xie C, Jiang Z, Li R, Yao X, Fan X, Wu Q, Yan P, Liu L, Chen J, Xie Y, Leung EL-H. Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice. Acta Pharmaceutica Sinica B (IF: 14.903, Elsevier highly cited paper)
  15. Huang M*, He F*, Li D, Xie YJ, Jiang ZB, Huang JM, Zhao XP, Nasim AA, Chen JH, Hou JC, Fan XM, Leung ELH, Fan X-X. PA-MSHA induces inflamed tumor microenvironment and sensitizes tumor to anti-PD-1 therapy. Cell Death & Disease 2022; 13: 931. (IF: 9.696)
  16. Xie YJ*, Huang M*, Li D, Hou JC, Liang HH, Nasim AA, Huang JM, Xie C, Leung EL, Fan XX. Bacteria-based nanodrug for anticancer therapy. Pharmacol Res 2022: 106282. (IF: 10.334)
  17. Jiang ZB*, Xu C*, Wang W*, Zhang YZ, Huang JM, Xie YJ, Wang QQ, Fan XX, Yao XJ, Xie C, Wang XR, Yan PY, Ma YP, Wu QB, Leung EL. Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8. Pharmacol Res 2021; 169: 105656. (IF: 7.658)
  18. Jiang ZB*, Wang WJ*, Xu C*, Xie YJ, Wang XR, Zhang YZ, Huang JM, Huang M, Xie C, Liu P, Fan XX, Ma YP, Yan PY, Liu L, Yao XJ, Wu QB, Lai-Han Leung E. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer Lett (IF: 8.679 , ESI Highly Cited Paper)
  19. Li J-X*, Li R-Z*, Sun A*, Zhou H, Neher E, Yang J-S, Huang J-M, Zhang Y-Z, Jiang Z-B, Liang T-L, Ma L-R, Wang J, Wang X-R, Fan X-Q, Huang J, Xie Y, Liu L, Tang L, Leung EL-H, Yan P-Y. Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling. Pharmacological Research 2021; 171: 105574. (IF: 7.658)
  20. Jiang ZB*, Huang JM, Xie YJ, Zhang YZ, Chang C, Lai HL, Wang W, Yao XJ, Fan XX, Wu QB, Xie C, Wang MF, Leung EL. Evodiamine suppresses non-small cell lung cancer by elevating CD8(+) T cells and downregulating the MUC1-C/PD-L1 axis. J Exp Clin Cancer Res 2020; 39: 249. (IF: 11.161)
  21. Wang WJ*, Mao LF*, Lai HL, Wang YW, Jiang ZB, Li W, Huang JM, Xie YJ, Xu C, Liu P, Li YM, Leung ELH, Yao XJ. Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway. Pharmacol Res 2020; 161: 105129. (IF: 7.658)
  22. Li JX*, Huang JM, Jiang ZB, Li RZ, Sun A, Lai-Han Leung E, Yan PY. Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer. Integr Cancer Ther 2019; 18: 1534735419890020. (IF: 2.379)
  23. Leung EL*, Luo LX*, Li Y, Liu ZQ, Li LL, Shi DF, Xie Y, Huang M, Lu LL, Duan FG, Huang JM, Fan XX, Yuan ZW, Ding J, Yao XJ, Ward DC, Liu L. Identification of a new inhibitor of KRAS-PDE-delta interaction targeting KRAS mutant non-small cell lung cancer. Int J Cancer 2019; 145: 1334-1345. (IF: 7.658)
  24. Wang Q*, Xu J*, Li Y, Huang J, Jiang Z, Wang Y, Liu L, Leung ELH, Yao X. Identification of a Novel Protein Arginine Methyltransferase 5 Inhibitor in Non-small Cell Lung Cancer by Structure-Based Virtual Screening. Front Pharmacol 2018; 9: 173. (IF: 3.845)
Research Grants
2014 – 2015 Grant Principal Investigator, 基于功效差异白僵蚕抗癫痫物质基础研究, 江西省研究生创新专项（YC2014-S276)
Patents
  1. 蒋永兴, 梁丽娴, 黄居敏, 王子铭. 一种调理肠道菌群的中药组合物及其制备方法和应用: 中国, CN117100833A [P]. 2023-10-07
  2. 梁丽娴, 姜志宏, 萧文鸾, 刘良, 黄居敏. 组合物、其在制备肿瘤免疫治疗药物中的应用及药物组合物: 中国, 201910465476.5 [P]c. 2019- 05-30
  3. 梁丽娴, 姜志宏, 刘良, 萧文鸾, 黄居敏. 用于通过联合疗法来治疗癌症的方法及试剂盒: 中国, 201910951479.X [P]. 2019- 10-08
Awards
2021 China Gut Best poster
2014 National Scholarship for postgraduate students
2013 – 2014 Outstanding graduate, Jiangxi University of TCM
2013 Third Prize of Graduate Student Forum, Jiangxi University of TCM
2011 – 2012 Second-class scholarship, Chengdu University of TCM
2010 – 2011 First-class scholarship, Chengdu University of TCM
2009 – 2010 Second-class scholarship, Chengdu University of TCM